相关实验视频

Updated: Sep 8, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

对干扰素敏感的HEV驱动瘤三级淋巴体结构的形成,并预测鼻癌的免疫治疗反应

Shang-Xin Liu¹, Tao-Wei Wu², Dong-Hua Luo³

¹State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.

Cell reports. Medicine

|June 21, 2025

概括

三级淋巴体结构 (TLS) 对于免疫检查点阻塞 (ICB) 治疗至关重要. 研究人员确定了与CXCL9相关的干扰素响应的高内皮静脉 (IFN-HEV),预测了鼻癌中的ICB反应和存活率.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症研究癌症研究

背景情况:

免疫检查点阻塞 (ICB) 疗法的有效性依赖于三级淋巴体结构 (TLS) 内的抗瘤免疫力.
瘤中TLS形成的驱动因素尚未完全理解.
三级淋巴体结构 (TLS) 在抗瘤免疫力和对ICB治疗的反应中发挥着关键作用.

研究的目的:

调查鼻癌 (NPC) 中TLS的特征.
确定TLS形成的新型驱动因素及其与ICB治疗反应的关联.
在NPC中开发ICB治疗结果的预测生物标志物.

主要方法:

空间转录组学和泛癌单细胞地图集成.
在鼻癌 (NPC) 样本中分析TLS特征.
开发和验证一个预测得分系统 (CTRscore).

主要成果:

识别与CXCL9产生相关的对干扰素敏感的高内皮静脉 (IFN-HEVs).
通过CXCL9分泌的IFN-HEV促进CXCR3+CD4+T细胞进入TLS.
IFN-HEV表型与改善的生存率和增强的ICB响应性相关.
一个新的CXCL9-TLS响应预测评分系统 (CTRscore) 准确预测NPC队列中的ICB结果.

结论:

对干扰素敏感的高内皮静脉 (IFN-HEVs) 是瘤TLS形成和免疫细胞招募的关键参与者.
与IFN-HEV相关的表型作为预测ICB治疗成功的有希望的生物标志物.
开发的CTRscore为NPC患者进行ICB治疗的分层提供了一个有价值的工具.

关键词:

在CXCL9中使用.高内皮膜静脉的高内皮膜静脉.免疫疗法免疫疗法免疫疗法反应的免疫疗法反应干扰子干扰子干扰子对干扰素有反应的高内皮细胞静脉.鼻癌鼻癌鼻癌预测模型预测模型三级淋巴体结构的第三级淋巴体结构

更多相关视频

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...